Prognostic factors for cases with metastatic renal cell carcinoma in the era of targeted medicine. - Archive ouverte HAL Access content directly
Journal Articles International Journal of Urology Year : 2009

Prognostic factors for cases with metastatic renal cell carcinoma in the era of targeted medicine.

(1) , (2) , (3, 4)
1
2
3
4

Abstract

Prognostic factors in the setting of treated metastatic renal cell carcinoma (mRCC) can theoretically predict drug response, progression-free survival or overall survival. These factors are potentially useful for informing patients and for tailoring medical treatment according to risk assessment. Prognostic factors were well defined in the era of immunotherapy. Since 2006, tyrosine kinase inhibitors and anti-angiogenic drugs have revolutionized the treatment of mRCC by improving progression-free survival and overall survival. Physicians now need new predictive tools adapted to targeted therapies. The aim of our study was to review the current knowledge about prognostic factors in mRCC by focusing on anatomical, clinical, biological, histological, radiological and molecular parameters. The most recent integrated prognostic models will be reviewed as well.

Dates and versions

inserm-00410889 , version 1 (25-08-2009)

Identifiers

Cite

Yann Neuzillet, Stéphane Culine, Jean-Jacques Patard. Prognostic factors for cases with metastatic renal cell carcinoma in the era of targeted medicine.. International Journal of Urology, 2009, 16 (11), pp.855-61. ⟨10.1111/j.1442-2042.2009.02365.x⟩. ⟨inserm-00410889⟩
62 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More